stockportfolio.pro
Stocks / DGICA vs DMII
DGICA vs DMII
Donegal Group Inc. and Drugs Made In America Acquisition II Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Financial Services.
| Donegal Group Inc. (DGICA) | Drugs Made In America Acquisition II Corp. (DMII) | |
|---|---|---|
| Market cap | $0.7B | $0.6B |
| Revenue (latest FY) | $978.01M | $0 |
| Net income (latest FY) | $79.34M | $4.19M |
| Revenue growth (5y CAGR) | 4.7% | — |
| Net margin | 8.1% | — |
| Return on equity | 12.4% | 0.9% |
| P/E ratio | 9.9 | 72.0 |
| Dividend yield | 4.4% | — |
| Profitable years (of last 10) | 8 | 1 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DGICA — free Open DMII — freeFrequently asked questions
Which is bigger, DGICA or DMII?
Donegal Group Inc. is larger by market capitalization — $0.7B versus $0.6B.
Which grows faster, DGICA or DMII?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.